These groups are equivalent to high and low HLA‐II expression in malignant NK cells, which is consistent with their known involvement in NKTCL development.[15, 18, 19] EBVhigh tumors with high HLA‐II expression in malignant NK cells may have a profound immune activation, since NK cells with upregulation of HLA‐II genes could enhance the immune response of CD4+ T cells through antigen presentation.[60] Furthermore, EBVhigh tumors had higher immunogenicity potential, as reflected by higher transcription of HLA‐I molecule and enrichment of endogenous antigen processing pathway. This evidence concerns the gene CD4 and extranodal nasal NK/T cell lymphoma.